HP
RXRX icon

Havemeyer Place’s Recursion Pharmaceuticals RXRX Stock Holding History

Havemeyer Place’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-183,936
Closed -$565K – 660
2026
Q1 		$565K Buy
183,936
+183,045
+20,544% +$707K 0.07% 386
2025
Q4 		$3.64K Buy
+891
New +$4.41K ﹤0.01% 504

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Havemeyer Place's RXRX Position: Q2 2026 in Review

Havemeyer Place sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 183,936 shares — an estimated $565K sold.

Havemeyer Place first reported a position in RXRX in Q4 2025 and held it in 2 quarters. The position peaked at $565K in Q1 2026. 340 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Havemeyer Place reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Havemeyer Place sold 183,936 Recursion Pharmaceuticals shares in Q2 2026, an estimated $565K.
  • Havemeyer Place first reported a position in Recursion Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Havemeyer Place's Recursion Pharmaceuticals position peaked at $565K in Q1 2026.
  • 340 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Havemeyer Place's 13F filing for Q2 2026, filed 13 Aug 2026.